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Mutations of KCNJ10 Together with Mutations of SLC26A4
Cause Digenic Nonsyndromic Hearing Loss Associated
with Enlarged Vestibular Aqueduct Syndrome
Tao Yang,1,2 Jose G. Gurrola II,2 Hao Wu,1 Sui M. Chiu,4 Philine Wangemann,5 Peter M. Snyder,3
and Richard J.H. Smith2,3,*
Mutations in SLC26A4 cause nonsyndromic hearing loss associatedwith an enlarged vestibular aqueduct (EVA, also known asDFNB4) and
Pendred syndrome (PS), themost common type of autosomal-recessive syndromic deafness. Inmany patients with an EVA/PS phenotype,
mutation screening of SLC26A4 fails to identify two disease-causing allele variants. That a sizable fraction of patients carry only one
SLC26A4mutation suggests that EVA/PS is a complex disease involving other genetic factors. Here,we show thatmutations in the inwardly
rectifyingKþ channel geneKCNJ10 are associatedwithnonsyndromichearing loss in carriersof SLC26A4mutationswithanEVA/PSpheno-
type. In probands from two families, we identiﬁed double heterozygosity in affected individuals. These persons carried singlemutations in
both SLC26A4 and KCNJ10. The identiﬁed SLC26A4 mutations have been previously implicated in EVA/PS, and the KCNJ10 mutations
reduceKþ conductanceactivity,which is critical for generatingandmaintaining the endocochlear potential. Inaddition,we showthathap-
loinsufﬁciencyof Slc26a4 in the Slc26a4þ/mousemutant results in reducedprotein expressionofKcnj10 in the stria vascularis of the inner
ear. Our results link KCNJ10mutations with EVA/PS and provide further support for themodel of EVA/PS as amultigenic complex disease.Enlargement of the vestibular aqueduct (EVA) is the most
common bony inner-ear malformation resolved by
computed tomography. It is associatedwith nonsyndromic
hearing loss (DFNB4 [MIM 600791]) and with Pendred
syndrome (PS [MIM274600]), a commontypeof syndromic
hearing loss that includes thyroid dysfunction as part of the
disease phenotype. EVA/PS has been causally linked to
mutations in the anion transporter gene SLC26A4, which
encodes the protein pendrin (MIM 605646).1,2 In the inner
ear, pendrin is expressed in cells of the external sulcus,
epithelium cells of the endolymphatic duct and sac, and
nonsensory cells at themargin of themaculae of the utricle
and saccule.3,4 In all of these cell types, the apical surface is
exposed to endolymph, consistentwith pendrin’s role as an
anion transporter. The mouse mutant homozygous for the
targeted deletion of Slc26a4 recapitulates the human
phenotype—it is profoundly deaf and has EVA.5
Although pathogenic mutations in SLC26A4 have been
shown to abolish membrane targeting or abrogate ion
transport,6,7 the exact link between the loss of functional
pendrin and hearing impairment is not well understood.
There is evidence to support a role for pendrin inmediating
secretion of HCO3
 from epithelial cells of the spiral prom-
inence into the cochlear endolymph, where loss of pendrin
in Slc26a4/mice causes endolymphatic acidiﬁcation and
Ca2þ overloading. These ionic changes could potentially
inhibit mechanosensory transduction and lead to hair cell
degeneration.8 However, it has also been postulated that
cochlear development in Slc26a4/ mice is compromised
by local hypothyroidism (S. Billings et al., 2008, Assoc.
Res. Otolaryngol., abstract).The AmWangemann and colleagues have raised another
intriguing possibility based on protein expression studies
in the Slc26a4/ mouse, which show that loss of pendrin
leads to reduced protein levels of the Kþ channel
Kcnj10.9,10 KCNJ10 (MIM 602208) is an inwardly recti-
fying Kþ channel subunit abundantly expressed in the
plasma membrane of intermediate cells of the stria vascu-
laris. Temporal expression of murine Kcnj10 correlates
with the onset of the endocochlear potential, a potential
essential for auditory function. This potential is absent in
Kcnj10/mice and is abolished when Kþ channel blockers
are used to inhibit Kcnj10 channel activity, suggesting that
deafness in the Slc26a4/ mutant mouse is secondary to
loss of Kcnj10 function.11–14
The onset of hearing loss varies considerably in EVA/PS.
Although many patients are congenitally deaf, in others
the onset of hearing loss occurs during childhood, suggest-
ing that EVA/PS is compatible with hearing and that envi-
ronmental or other genetic factors contribute to the loss of
hearing. On the basis of the close link between protein
expression levels of KCNJ10 and pendrin and the func-
tional importance of KCNJ10 in the generation of the
endocochlear potential, we hypothesized that mutations
in KCNJ10might play a role in the pathogenesis of EVA/PS.
Subjects and Methods
Subjects
Persons with EVA/PS were ascertained through hearing loss refer-
rals based on results of temporal bone computed tomography or
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a complete history and physical examination. For classiﬁcation of
EVA, enlargement of the vestibular aqueduct had to be greater
than 1.5 mm at a point midway between the endolymphatic sac
and vestibule. For classiﬁcation of Mondini dysplasia, the cochlea
also had to be abnormal, with incomplete partition and a scala
communis. All procedures were approved by the institution review
board at the University of Iowa, and all subjects or the parents of
minors gave written informed consent for genetic testing.
Mutational Analysis of SLC26A4 and KCNJ10
DNA was extracted from whole blood via standard procedures.15
Mutation screening of SLC26A4 was completed by denaturing
high-performance liquid chromatography (DHPLC) and bidirec-
tional sequencing, as previously described.15,16 For EVA/PS
patients who carry only one SLC26A4 coding-sequence mutation,
KCNJ10 was screened by bidirectional sequencing of amplicons
generated by PCR ampliﬁcation of all exons and splice sites. Primer
sequences are listed in Table S1 (available online).
Expression of KCNJ10 in Xenopus Oocytes
The KCNJ10 coding region was PCR ampliﬁed from cDNA and
cloned into the pSP64 Poly(A) vector (Promega,Madison,WI). The
p.P194H and p.R348C mutations were introduced into KCNJ10
expression constructs by site-directed mutagenesis with the
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA). In vitro transcription of KCNJ10 was performed with the
mMESSAGEmMACHINEkit (Applied Biosystems/Ambion,Austin,
TX), and the generated transcript (50 nl of a 1 ug/ul solution) was
injected into defolliculated Xenopus oocytes. After injection,
oocytes were incubated in MES-buffered saline (MBS) at 18C.
Electrophysiological studies were performed 24 hr later.
Electrophysiology
Whole-cell electrophysiological studies were performed via two-
electrode voltage clamping. In brief, currents were ampliﬁed
with an Oocyte Clamp OC-725C (Warner Instruments, Hamden,
CT), digitized with a MacLab/200 interface (ADInstruments, Colo-
rado Springs, CO), and recorded and analyzed with Chart software
(ADInstruments). The microelectrodes were ﬁlled with 3 M KCl,
and during experiments, oocytes were bathed in a solution con-
taining 90 mM KCl, 3 mM MgCl2, 5 mM HEPES, and 150 mM
niﬂumic acid at pH 7.4. Oocytes were held at a potential of
0 mV by voltage clamping, and voltage steps of 2 s were applied
in 20 mV increments. Differences between currents of wild-type
(WT) and mutant KCNJ10 (n ¼ 6) were compared with the
Student’s unpaired t test. Slopes of the current-voltage relationship
in the linear range (120 mV to 0 mV) were calculated by linear
regression analysis.
Tissue Preparation and Protein Extraction of Mouse
Stria Vascularis
Cochleae were removed from P18 Slc26a4þ/þ, Slc26a4þ/, and
Slc26a4/ mice (n > 4 for each group) via procedures approved
by the InstitutionalAnimalCare andUseCommittee of theUniver-
sity of Iowa. Stria vascularis fractionswere obtainedbymicrodissec-
tion under the surgical microscope and were then immediately
transferred to 40 ml Tris-Triton buffer (50 mM Tris, 150 mM NaCl,
1% Triton-X) and homogenized on ice for 30 s by ultrasonic homo-
genization (Model 150VT, BioLogics, Manassas, VA). Extracted
protein was stored at 80C until use.652 The American Journal of Human Genetics 84, 651–657, May 15Quantitative Immunoblot Analysis
Immunoblotting was performed as previously described,9 with
slight modiﬁcation, and all procedures were performed at room
temperature unless otherwise noted. In brief, equal volumes of
protein extract andLaemelli buffer containing5%b-mercaptoetha-
nol were mixed and heated at 70C for 5 min, followed by SDS-
PAGE gel electrophoresis (10% Ready-gel, BioRad Laboratories,
Hercules, CA). Separated proteins were electrophoretically trans-
ferred to a nitrocellulose membrane (ProTran BA85, 0.45 mm pore
size,Whatman, Florham Park, NJ), blocked at 4C overnight in 5%
nonfat dry milk in TBS with 0.1% Tween-20, then incubated with
primary antibodies (rabbit anti-Kcnj10, 1:1000, Cat# APC-035,
Alomone Labs, Jerusalem, Israel; rabbit anti-tubulin, 1:500, Cat#
ab6046, Abcam, Cambridge, MA) in blocking buffer for 1 hr.
Unbound primary antibody was removed by three 10 min washes
with Tween TBS, and the membrane was then incubated with
HRP-conjugated secondary antibody (Peroxidase AfﬁniPure Goat
anti-Rabbit IgG, 1:4000, Cat# 111-035-045, Jackson Immuno-
Research Laboratories, West Grove, PA) for 45 min. After three
washes with Tween TBS, the membrane was developed by
enhanced chemiluminescence (Amersham ECL Western Blotting
Detection Reagents, GE Healthcare, Florham Park, NJ), read on
a low-light digital camera (LAS-1000, Fujiﬁlm Medical Systems,
Stamford, CT), and quantiﬁedwith ImageGauge software (Fujiﬁlm
Medical Systems, Stamford, CT). All experiments were repeated in
triplicate. Kcnj10 protein expression differences in Slc26a4þ/þ,
Slc26a4þ/, and Slc26a4/mice were compared by one-way anal-
ysis of variance (ANOVA) and the Dunn’s post hoc test.
Results
Genetic Analysis of KCNJ10 Mutations
We completed KCNJ10 mutation screening in 89 patients
who had a clinical diagnosis of EVA/PS and were known
carriers of only one SLC26A4 coding sequence mutation;
promoter mutations and deletions of SCL26A4 were also
excluded in thispatient cohort. In twopatients,we identiﬁed
missense mutations in KCNJ10—a p.P194H (c.581C/A)
mutation in patient 7740-1 and a p.R348C (c.1042C/T)
mutation in patient 82120-1. Patient 7740-1 also carries a
p.F335L (c.1003T/C)mutation in SLC26A4, and in Patient
82120-1, we identiﬁed a c.919-2A/Gmutation (Table 1). In
Family82120,wewere able to reconstructhaplotypes,which
showed that the mother carries KCNJ10 p.R348C and the
father carries SLC26A4 c.919-2A/G. An unaffected sibling
carries only the KCNJ10 p.R348C variant (Figure 1). Both
amino acid changes in KCNJ10 are conserved across most
mammalian species (Figure S1), and neither change was
found in ethnically matched normal-hearing controls of
European (n ¼ 200, 400 chromosomes) and Chinese (n ¼
200, 400 chromosomes) descent.









82120-1 EVA p.R348C / þ c.919-2A/G / þ
7740-1 EVA, Mondini dysplasia p.P194H / þ p.F335L / þ, 2009
Figure 1. Double Heterozygosity for Mutations in KCNJ10 and SLC26A4 in Family 82120 with EVA/PS
(A) Pedigree and genotypes of the family, showing that the parents and their unaffected child carry a single mutation in either SLC26A4 or
KCNJ10 and that the affected child carries both mutations.
(B) Representative chromatograms of the SLC26A4 c.919-2A/G and KCNJ10 p.R348C mutations identified in this family.Electrophysiology
To determine whether the identiﬁed KCNJ10 mutations
change Kþ channel currents, we expressed WTand mutant
KCNJ10 in Xenopus oocytes by mRNA injection and
recorded evoked Kþ currents in a two-electrode voltage
clampexperiment. Figure 2A shows a representative current
recording in an oocyte expressing WT KCNJ10. Control
oocytes injected with equal volumes of water showed littleThe Amcurrentunder evokingvoltagecommands (datanot shown).
So that the speciﬁcity of themeasured currentswas ensured,
150 mM niﬂumic acid was added in the bathing solution,
blocking endogenous Cl currents. In addition, the evoked
current could be abolished when 1 mM Ba2þ was applied.
Expression ofWT KCNJ10 inXenopus oocytes resulted in
a weak inwardly rectifying Kþ current similar to previously
reported data.17 In oocytes expressing either H194 or C348Figure 2. Voltage-Clamp Analysis of Kþ Conductance of WT and Mutant KCNJ10
(A) Representative trace of current (top) and voltage commands (bottom) versus time in Xenopus oocyte expressing WT KCNJ10. A 1 mM
final concentration of channel blocker BaCl2 was added into the extracellular bath at the time point near 20 s, as indicated (black bar).
(B) Steady-state current-voltage relationship for WT and mutant KCNJ10 (mean5 SE, n¼ 6). For clarity, error bars are shown only for WT
and R348C mutant KCNJ10. The differences between the currents of WT and mutant KCNJ10 are statistically significant at voltages
between 120 mV and 20 mV (p < 0.05), as indicated by asterisks. The slopes of the current-voltage relationship in the linear range
between 120 mV and 0 mV were calculated by linear regression analysis and are shown at the right of each curve (from top: WT, R348C,
and P194H; R2 values are shown in parentheses).erican Journal of Human Genetics 84, 651–657, May 15, 2009 653
Figure 3. Quantitative Immunoblot
Analysis of Kcnj10 Expression in Mouse
Stria Vascularis
(A) Representative immunoblot showing
protein expression of Kcnj10 and b-tubulin
in equal sample volumes from Slc26a4þ/þ,
Slc26a4þ/, and Slc26a4/ mice. Molec-
ular weights (kDa) of protein standards
are marked on the right side. The two major
bands of 120 kDa and 50 kDa and the minor
smears of Kcnj10 reflect variable protein
glycosylation, stoichiometry, and ubiquiti-
nation, as previously reported,9 and all are
included in the quantitative analysis.
(B) Quantification of Kcnj10 expression
normalized against b-tubulin control
expression. Reduced expression of Kcnj10
in the stria vascularis of Slc26a4þ/ and
Slc26a4/ mice as compared to WT mice (mean percentage5 SE, n ¼ 3) is shown as scaled bars. The differences in Kcnj10 expression
between Slc26a4þ/ and Slc26a4þ/þ mice and between Slc26a4/ and Slc26a4þ/þ mice are statistically significant (p < 0.05), as indi-
cated by asterisks.mutant KCNJ10, Kþ channel conductance markedly
decreased (Figure 2B). Compared to WT, the Kþ currents
of the mutant KCNJ10 were signiﬁcantly reduced (p <
0.05) in the linear range (120 mV to 20 mV), and the
mean slopes (DI/DV) of the mutant KCNJ10 current-
voltage relationships were reduced by 44% and 51% for
C348 and H194, respectively (R2 > 0.99). These results
suggest that Kþ conductance is severely impaired by the
mutations that we identiﬁed in these two patients.
Kcnj10 Expression in Slc26a4þ/ Mice
In family 82120, the c.919-2A/G splice-site mutation in
SLC26A4 is predicted to cause skipping of exon 8, leading
to premature protein truncation and haploinsufﬁciency. In
the mouse mutant with a targeted deletion of Slc26a4,
exon 8 is replaced by a neoR-containing cassette that
similarly results in loss of functional protein.5 Given that
deﬁciency of pendrin in Slc26a4/ mice leads to loss of
Kcnj10 protein in stria vascularis, we investigated whether
haploinsufﬁciency would affect the Kcnj10 protein level in
the stria vascularis by studying Slc26a4þ/ animals.
ThestriavascularisofP18mousecochleae fromSlc26a4/,
Slc26a4þ/, and Slc26a4þ/þ mice was isolated by microdis-
section, and total protein extracted from these tissue frac-
tions was used for quantitative immunoblot analysis
(Figure 3). In Slc26a4þ/mice, we observed reduced protein
expression of Kcnj10 as compared to Slc26a4þ/þ WT
controls (75%, p < 0.05). In Slc26a4/ mice, Kcnj10
protein expression was further reduced (49%, p < 0.05).
These results indicate that haploinsufﬁciency of pendrin
leads to reduced KCNJ10 protein expression.
Discussion
Many studies have suggested that EVA/PS is a complex
disease.18–20 However, in the ten-year span following654 The American Journal of Human Genetics 84, 651–657, May 15,discovery of SLC26A4 as the primary gene responsible for
EVA/PS, identiﬁcation of factors that promote the onset of
hearing loss in patients with EVA/PS has been limited to
infections and head injuries and to genetic factors such as
the expression of FOXI1, which controls the expression of
SLC26A4.21,22 The goal of identifying genetic factors has
been limited by the availablity of a sufﬁcient number of
families showing clear digenic inheritance that would
make conventional positional cloning approaches feasible.
As an alternative, we have adopted a candidate gene
approach, selecting for in-depth study genes that have a
strong functional link to SLC26A4. In addition, we have
identiﬁed a cohort of patients in which to screen these
candidates.
Using this strategy in our earlier work, we selected FOXI1
for study on the basis of the observation that endolym-
phatic sac expression of Slc26a4 is absent in the Foxi1/
mouse.Wewere able to show that heterozygosity for muta-
tions in this transcription factor and SLC26A4 are causally
related to the EVA/PS phenotype in humans.22 In this
study, on the basis of work demonstrating that loss of
Kcnj10 protein expression is a key event in the etiology
of deafness in Slc26a4/ mice, we hypothesized that
genetic factors affecting expression of functional KCNJ10
channels might also contribute to penetrance of hearing
loss in EVA/PS patients.
We identiﬁed two patients who have been diagnosed
with EVA/PS and who segregate mutations in both
SLC26A4 and KCNJ10. The p.P194H and p.R348C muta-
tions in KCNJ10 change two well-conserved aminio acids
and were not observed in 800 control chromosomes. Our
electrophysiologic study showed that these mutations are
detrimental to channel activity and reduce Kþ conduc-
tance by 44%–51% (Figure 2). Notably, given that KCNJ10
may form homomeric tetramers,17 heterozygosity for these
mutations is predicted to affect over 90% of multimeric
KCNJ10 channels.2009
Thep.F335L SLC26A4mutationcarriedbypatient 7740-1
has been reported in 14 of 668 EVA/PS patients but in none
of 358 normal-hearing controls (p < 0.01, Fisher’s exact
test).19,22–25 Functional studies of this variant have shown
decreased Cl/HCO3
 exchange, suggesting that leucine at
this position results in a hypofunctional protein.24 Family
82120 is of Chinese origin, and the affected child carries
the SLC26A4 c.919-2A/Gmutation, which is highly prev-
alent in theChinese population,where it accounts formore
than half of all reported SLC26A4 mutant alleles.26 This
mutation is within the 30 splicing site of exon 8 and is pre-
dicted to lead to premature protein truncation andhaploin-
sufﬁciency.
Our quantitative immunoblot analysis in Slc26a4/,
Slc26a4þ/, and Slc26a4þ/þmice indicates that haploinsuf-
ﬁciency for Slc26a4 leads to decreased expression of Kcnj10
in the stria vascularis, providing a pathogenic link between
mutations in these two genes. Haploinsufﬁciency of only
Slc26a4 in Slc26a4þ/ mice or Kcnj10 in Kcnj10þ/ mice,
however, does not affect the magnitude of the endoco-
chlear potential; in contrast, homozygous loss of Slc26a4
in Slc26a4/ mice or of Kcnj10 in Kcnj10/ mice leads
to a complete loss of this potential.8,12 Conﬁrmation of
a digenic disease mechanism in the patients that we have
describedwill require generationof amousemodel carrying
orthologous mutations in Slc26a4 and Kcnj10.
The mechanism for the reduction of Kcnj10 protein
expression in Slc26a4þ/ mice is not understood. Previous
studies have suggested that maintenance of normal endo-
lymphatic Kþ concentration in Slc26a4/ mice leads to
free-radical stress in the stria vascularis and that this free-
radical stress causes loss of strial Kcnj10 and thereby loss
of the endocochlear potential.8,9 It is noteworthy that
SLC26A4 and KCNJ10 are expressed in distinct cell types
in the cochlear lateral wall, the former found in the
external sulcus cells and the latter in the intermediate cells
of the stria vascularis. These distinct localizations suggest
that the existence of a functional link such as oxidative
stress is plausible. The oxidative stress hypothesis is sup-
ported by protein expression studies of cultured mouse
stria vascularis. When surrounded by a uniform culture
medium, striae vascularis harvested from Slc26a4þ/ and
Slc26a/ mice show similar expression levels of Kcnj10.9
Recent studies have suggested that most rare missense
alleles in humans are deleterious and make a substantial
contribution to multifactorial diseases.27,28 The detection
of numerous rare variants in the same candidate gene,
unlikely in conventional association studies based on
common polymorphisms, has proven to be a useful
strategy for discovery of disease-causing genes in complex
diseases such as colorectal cancers and disorders of lipid
metabolism.29,30 The effectiveness of this strategy is clearly
demonstrated by our ﬁnding of single KCNJ10 mutations
in two patients who also carry single mutations in
SLC26A4 and have an EVA/PS phenotype.
While this article was being written, Scholl and
colleagues reported homozygous or compound heterozy-The Amgous mutations in KCNJ10 in members of four kindreds
with a recessive complex syndrome that includes seizures,
sensorineural deafness, ataxia, mental retardation, and
electrolyte imbalance.31 This complex phenotype is similar
to that seen in Kcnj10/ mouse mutants that exhibit
severe ataxia, stress-induced seizures, spongiform vacuola-
tion, axonal swellings, and degeneration, in addition to
hearing loss.32,33 In contrast, the EVA/PS phenotype asso-
ciated with double heterozygosity for mutations in
KCNJ10 and SLC26A4 represents a distinct disease entity
in which only hearing loss is observed.
Our functional characterization of the pathogenic inter-
action between SLC26A4 and KCNJ10 mutations suggests
that this digenic combination of mutations is speciﬁcally
associated with inner-ear dysfunction. On the basis of our
data, we propose thatKCNJ10 is an important genetic factor
in the pathogenesis of EVA/PS. The mutations in SLC26A4
lead to hypofunction or haploinsufﬁciency. In association
with EVA/PS, haploinsufﬁciency of SLC26A4 and oxidative
stress converge to reduce strial expression of KCNJ10
protein. The consequence of decreased KCNJ10 expression
is a reduced supply of Kþ tomarginal cells in the stria vascu-
laris. In turn, these cells reduce their rate of Kþ secretion.
This self-limiting mechanism might account for the inter-
mittenthearing-threshold recovery that iswell documented
in EVA/PS patients and leads to ﬂuctuating and progressive
hearing loss.21,34,35 Thisparadigmprovidesnew insight into
the pathogenesis of EVA/PS and, as a corollary, suggests that
if strial expression of KCNJ10 can be maintained, perhaps
through controlling endolymph pH or limiting oxidative
stress through medical therapy, hearing loss might be
preventable in some persons with an EVA/PS phenotype.
Supplemental Data
Supplemental Data include one ﬁgure and one table and can be
found with this article online at http://www.ajhg.org/.
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